Literature DB >> 10559258

RIP2 is a Raf1-activated mitogen-activated protein kinase kinase.

T A Navas1, D T Baldwin, T A Stewart.   

Abstract

RIP2 is a serine-threonine kinase associated with the tumor necrosis factor (TNF) receptor complex and is implicated in the activation of NF-kappaB and cell death in mammalian cells. However, the function of its kinase domain is still enigmatic as it is not required in engaging these responses. Here we show that RIP2 activates the extracellular signal-regulated kinase (ERK) pathway and that the kinase activity of RIP2 appears to be important in this process. RIP2 activates AP-1 and serum response element regulated expression by inducing the activation of the Elk1 transcription factor. RIP2 directly phosphorylates and activates ERK2 in vivo and in vitro. RIP2 in turn is activated through its interaction with Ras-activated Raf1. Kinase-defective point and deletion variants of RIP2 also significantly blocked the activation of ERK2 by TNFalpha but not epidermal growth factor. These results describe a novel pathway of ERK activation and the first catalytic function ascribed to any of the RIP-like kinases associated with the TNF receptor superfamily.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559258     DOI: 10.1074/jbc.274.47.33684

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Cross-talk between receptor tyrosine kinase and tumor necrosis factor-α signaling networks regulates apoptosis but not proliferation.

Authors:  Elsa M Beyer; Gavin MacBeath
Journal:  Mol Cell Proteomics       Date:  2012-02-08       Impact factor: 5.911

2.  PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.

Authors:  Edita Aksamitiene; Boris N Kholodenko; Walter Kolch; Jan B Hoek; Anatoly Kiyatkin
Journal:  Cell Signal       Date:  2010-05-12       Impact factor: 4.315

3.  Inhibition of RIP2/RIck/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK.

Authors:  Gretchen M Argast; Nelson Fausto; Jean S Campbell
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

Review 4.  RIP kinases: key decision makers in cell death and innate immunity.

Authors:  F Humphries; S Yang; B Wang; P N Moynagh
Journal:  Cell Death Differ       Date:  2014-08-22       Impact factor: 15.828

Review 5.  Receptor-interacting protein (RIP) kinase family.

Authors:  Duanwu Zhang; Juan Lin; Jiahuai Han
Journal:  Cell Mol Immunol       Date:  2010-04-12       Impact factor: 11.530

6.  Dual Inhibition of Rip2 and IRAK1/4 Regulates IL-1β and IL-6 in Sarcoidosis Alveolar Macrophages and Peripheral Blood Mononuclear Cells.

Authors:  Jaya Talreja; Harvinder Talwar; Nisar Ahmad; Ruchi Rastogi; Lobelia Samavati
Journal:  J Immunol       Date:  2016-07-11       Impact factor: 5.422

7.  A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells.

Authors:  Scott A Stuart; Stephane Houel; Thomas Lee; Nan Wang; William M Old; Natalie G Ahn
Journal:  Mol Cell Proteomics       Date:  2015-04-07       Impact factor: 5.911

8.  RIP2, a checkpoint in myogenic differentiation.

Authors:  Barbara Munz; Eberhard Hildt; Matthew L Springer; Helen M Blau
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

9.  A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

Authors:  Steven R Whittaker; Jean-Philippe Theurillat; Eliezer Van Allen; Nikhil Wagle; Jessica Hsiao; Glenn S Cowley; Dirk Schadendorf; David E Root; Levi A Garraway
Journal:  Cancer Discov       Date:  2013-01-03       Impact factor: 39.397

10.  A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation.

Authors:  Mizuho Hasegawa; Yukari Fujimoto; Peter C Lucas; Hiroyasu Nakano; Koichi Fukase; Gabriel Núñez; Naohiro Inohara
Journal:  EMBO J       Date:  2007-12-13       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.